196 related articles for article (PubMed ID: 29674164)
41. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
Fujisaki S; Takashita E; Yokoyama M; Taniwaki T; Xu H; Kishida N; Sato H; Tashiro M; Imai M; Odagiri T
Biochem Biophys Res Commun; 2012 Dec; 429(1-2):51-6. PubMed ID: 23131559
[TBL] [Abstract][Full Text] [Related]
42. In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan.
Ikematsu H; Kawai N; Kashiwagi S
J Infect Chemother; 2012 Aug; 18(4):529-33. PubMed ID: 22370919
[TBL] [Abstract][Full Text] [Related]
43. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
Zürcher T; Yates PJ; Daly J; Sahasrabudhe A; Walters M; Dash L; Tisdale M; McKimm-Breschkin JL
J Antimicrob Chemother; 2006 Oct; 58(4):723-32. PubMed ID: 16891631
[TBL] [Abstract][Full Text] [Related]
44. Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.
Correia V; Santos LA; Gíria M; Almeida-Santos MM; Rebelo-de-Andrade H
J Med Virol; 2015 Jan; 87(1):45-56. PubMed ID: 25042157
[TBL] [Abstract][Full Text] [Related]
45. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of favipiravir against influenza virus resistant to both baloxavir and neuraminidase inhibitors.
Kiso M; Yamayoshi S; Kawaoka Y
J Antimicrob Chemother; 2023 Jul; 78(7):1649-1657. PubMed ID: 37209424
[TBL] [Abstract][Full Text] [Related]
47. Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.
Tamura D; DeBiasi RL; Okomo-Adhiambo M; Mishin VP; Campbell AP; Loechelt B; Wiedermann BL; Fry AM; Gubareva LV
J Infect Dis; 2015 Oct; 212(8):1209-13. PubMed ID: 25943200
[TBL] [Abstract][Full Text] [Related]
48. Influenza B viruses from different genetic backgrounds are variably impaired by neuraminidase inhibitor resistance-associated substitutions.
Pascua PNQ; Marathe BM; Bisen S; Webby RJ; Govorkova EA
Antiviral Res; 2020 Jan; 173():104669. PubMed ID: 31790712
[TBL] [Abstract][Full Text] [Related]
49. Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient.
Abed Y; Schibler M; Checkmahomed L; Carbonneau J; Venable MC; Fage C; Giannotti F; Goncalves AR; Kaiser L; Boivin G
Antivir Ther; 2019; 24(8):581-587. PubMed ID: 32031540
[TBL] [Abstract][Full Text] [Related]
50. Comparison of early and recent influenza A(H1N1)pdm09 isolates harboring or not the H275Y neuraminidase mutation, in vitro and in animal models.
Abed Y; Tu V; Carbonneau J; Checkmahomed L; Venable MC; Fage C; Marie-Ève-Hamelin ; Dufresne SF; Kobinger G; Boivin G
Antiviral Res; 2018 Nov; 159():26-34. PubMed ID: 30219318
[TBL] [Abstract][Full Text] [Related]
51. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses.
Baz M; Abed Y; Simon P; Hamelin ME; Boivin G
J Infect Dis; 2010 Mar; 201(5):740-5. PubMed ID: 20100088
[TBL] [Abstract][Full Text] [Related]
52. Characteristics of oseltamivir-resistant influenza A (H1N1) pdm09 virus during the 2013-2014 influenza season in Mainland China.
Huang W; Li X; Cheng Y; Tan M; Guo J; Wei H; Zhao X; Lan Y; Xiao N; Wang Z; Wang D; Shu Y
Virol J; 2015 Jun; 12():96. PubMed ID: 26103966
[TBL] [Abstract][Full Text] [Related]
53. Influenza A virus hemagglutinin mutations associated with use of neuraminidase inhibitors correlate with decreased inhibition by anti-influenza antibodies.
Ilyushina NA; Komatsu TE; Ince WL; Donaldson EF; Lee N; O'Rear JJ; Donnelly RP
Virol J; 2019 Nov; 16(1):149. PubMed ID: 31783761
[TBL] [Abstract][Full Text] [Related]
54. Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea.
Kim HM; Lee N; Kim MS; Kang C; Chung YS
Virol J; 2020 Jul; 17(1):94. PubMed ID: 32631440
[TBL] [Abstract][Full Text] [Related]
55. Secondary substitutions in the hemagglutinin and neuraminidase genes associated with neuraminidase inhibitor resistance are rare in the Influenza Resistance Information Study (IRIS).
Roosenhoff R; Schutten M; Reed V; Clinch B; van der Linden A; Fouchier RAM; Fraaij PLA
Antiviral Res; 2021 May; 189():105060. PubMed ID: 33713731
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of recombinant 2009 pandemic influenza A (H1N1) viruses harboring zanamivir resistance mutations in mice and ferrets.
Pizzorno A; Abed Y; Rhéaume C; Bouhy X; Boivin G
Antimicrob Agents Chemother; 2013 Apr; 57(4):1784-9. PubMed ID: 23357777
[TBL] [Abstract][Full Text] [Related]
57. Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts.
Tang J; Zhang J; Zhou J; Zhu W; Yang L; Zou S; Wei H; Xin L; Huang W; Li X; Cheng Y; Wang D
Virol J; 2019 Jul; 16(1):87. PubMed ID: 31266524
[TBL] [Abstract][Full Text] [Related]
58. Platform for determining the inhibition profile of neuraminidase inhibitors in an influenza virus N1 background.
Hoffmann A; Schade D; Kirchmair J; Clement B; Sauerbrei A; Schmidtke M
J Virol Methods; 2016 Nov; 237():192-199. PubMed ID: 27659246
[TBL] [Abstract][Full Text] [Related]
59. Neuraminidase amino acids 149 and 347 determine the infectivity and oseltamivir sensitivity of pandemic influenza A/H1N1 (2009) and avian influenza A/H5N1.
Yongkiettrakul S; Nivitchanyong T; Pannengpetch S; Wanitchang A; Jongkaewwattana A; Srimanote P
Virus Res; 2013 Aug; 175(2):128-33. PubMed ID: 23639424
[TBL] [Abstract][Full Text] [Related]
60. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.
Yen HL; Ilyushina NA; Salomon R; Hoffmann E; Webster RG; Govorkova EA
J Virol; 2007 Nov; 81(22):12418-26. PubMed ID: 17855542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
